Lupus clinical trials at UCSF
3 in progress, 2 open to eligible people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis
open to eligible people ages 12-17
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics of obinutuzumab in adolescent participants aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN).
San Francisco, California and other locations
VIBRANT: VIB4920 for Active Lupus Nephritis
open to eligible people ages 18 years and up
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
San Francisco, California and other locations
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)
Sorry, in progress, not accepting new patients
SPOCS is an international, multicenter, prospective observational cohort study with bi-annual study visits over a 3-year follow-up designed to systematically describe the comprehensive SLE patient-journey regarding clinical features, disease progression and treatment patterns, SLE outcomes, health status assessments (PROs), and health care resource utilization (HCRU) in a general population of moderate-to-severe SLE patients.
San Francisco, California and other locations
Our lead scientists for Lupus research studies include David Wofsy, M.D..
Last updated: